Guerbet Boston Consulting Group Matrix
Actionable Strategy Starts Here
Curious where Guerbet’s products land—Stars, Cash Cows, Dogs or Question Marks? This snapshot teases the story; the full Guerbet BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a clear playbook for investment and divestment. Buy the complete report for a Word deep dive plus an Excel summary you can present and act on—fast, practical, and built for decision-makers.
Stars
Elucirem (gadopiclenol) MRI
Elucirem (gadopiclenol) sits squarely in the Star box: it addresses a high-growth MRI contrast segment (global MRI contrast market CAGR ~6% projected 2024–2030) with a best-in-class relaxivity profile that delivers pronounced image enhancement, driving strong clinical buzz and rapid uptake in premium imaging sites. It is grabbing share quickly where performance matters, but needs heavy medical education, robust post-marketing data and access work to sustain momentum; keep fueling it — this can mature into a major cash engine as the market steadies.
Dotarem franchise in fast-growth markets
In emerging regions Dotarem retains leader status as a macrocyclic gadoterate agent (FDA approval 2013) while MRI capacity expands rapidly—regional MRI device instalments growing an estimated 8–10% annually in 2024. Its strong safety profile and brand trust convert well as exam volumes rise, but defending tenders requires sustained commercial push and targeted pricing. Hold share now and as growth tapers the franchise transitions into a predictable cash cow.
Integrated injection platforms + software
Integrated injection platforms plus software form a hardware–software–consumables loop that locks in sites and follows the imaging market’s ~5.6% CAGR (2024–30), driving utilization and share as volumes rise. Capex-heavy to seed and train, the business yields sticky recurring consumables and service revenue; Guerbet, with ~1.06bn EUR 2023 sales, should keep investing in workflow, interoperability and the data layer to defend the beachhead.
Interventional imaging solutions (oncology focus)
Interventional imaging is structurally expanding alongside liver oncology and minimally invasive procedures; the interventional radiology market was ~USD 11.6B in 2023 and HCC accounted for 905,677 new cases in 2020, driving procedural volumes where Guerbet’s enhanced visualization and delivery solutions convert higher procedure counts into market share.
Clinical support and KOL training are primary growth levers; alignment with guideline-driven outcomes and real-world evidence cements leadership as adoption and repeat use rise.
- IR market ~USD 11.6B (2023)
- HCC incidence 905,677 new cases (2020)
- Levers: clinical support, KOL training, guideline/outcomes alignment
Strategic hospital partnerships
Long-term supply and service bundles in top health systems scale rapidly once embedded, with multi-year contracts (3–7 years) delivering roughly 30–50% greater revenue visibility and utilization predictability for vendors. As networks standardize protocols, preferred-vendor status locks market share and reduces churn. Set-up costs are real, so double down on multi-year value contracts and joint continuous-improvement plans to secure volume.
- Scale: rapid uptake in consolidated systems
- Lock-in: standardized protocols = preferred-vendor advantage
- Investment: absorb set-up costs for predictable volume
- Action: pursue 3–7 year contracts + joint improvement KPIs
Premium MRI contrast: high-growth market (~6% CAGR) — back access, KOLs, long contracts
Elucirem is a Star: premium MRI contrast in a ~6% CAGR global MRI market (2024–30) with rapid uptake; requires continued med-ed, RWE and access investment to scale. Dotarem holds regional leadership as capacity grows (~8–10% installs 2024 ME/EMEA). Invest in integrated platforms, KOLs and multi-year contracts to lock durable share.
| Asset | Role | Growth/Metric | 2023/24 |
|---|---|---|---|
| Elucirem | Star | MRI market CAGR | ~6% (2024–30) |
| Guerbet | Investor | Sales | €1.06bn (2023) |
| IR | Adj. growth | Market size | USD 11.6B (2023) |
What is included in the product
Detailed Word Document
BCG analysis of Guerbet's portfolio: spots Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Guerbet, highlights portfolio pain points and prioritizes fixes for faster decisions.
Cash Cows
Xenetix (iodinated CT)
Xenetix is a mature iodinated CT agent with a broad label and dependable volumes, reflecting that iodinated agents still represent over 90% of CT contrast use in 2024. Pricing is disciplined, tenders are established terrain and operations run efficiently, so promotional spend can stay modest while service reliability remains key. Strategy: milk margins, safeguard supply continuity, and steer clear of unnecessary price wars.
Optiray (ioversol) CT
Optiray (ioversol) is an established CT contrast brand in a slow-growth CT market, maintaining steady share through long-standing clinical familiarity and high formulary retention. Its cash generation remains strong relative to modest reinvestment needs, supporting margin stability and free cash flow. Prioritize quality maintenance, secure long-term supply and purchasing contracts, and channel surplus cash to fund higher-growth pipeline projects.
Dotarem in mature markets
Dotarem, a macrocyclic gadolinium-based MRI contrast agent established across US and EU markets, now sits past its steep growth phase and is recognized for stability and clinical trust.
It continues to generate steady cash flow despite newer MRI agents gaining attention, supported by minimal promotion and emphasis on access and reliable supply.
Guerbet directs those cash flows toward next-generation MRI agents and digital solutions, funding R&D and commercialization efforts.
Lipiodol niche indications
Lipiodol serves a smaller, highly specialized cash cow within Guerbet: resilient and profitable through niche indications such as transarterial chemoembolization for hepatocellular carcinoma and lymphography. Clinical utility keeps it relevant without heavy marketing spend; demand is predictable while supply assurance is the operational focus. Compliance and clean margins are critical to sustain cash generation.
- Used in TACE and lymphography
- Supports stable niche revenues
- Demand predictable; prioritize supply security
- Tight compliance to protect margins
- HCC incidence ~905,677 new cases (IARC 2020)
Disposables and service contracts
Disposables and service contracts deliver recurring, high-margin revenue for Guerbet; the group reported ~€1.15bn revenue in 2023, with consumables and services a core cash engine. Growth is low but churn remains minimal once platforms are installed, making forecasting straightforward. Promotion needs are light; focus is logistics and pricing to boost incremental cash.
- Recurring revenue
- High margin
- Low growth, low churn
- Easy forecasting
- Optimize logistics/pricing
CT iodinated >90% dominance funds €1.15bn R&D pivot to next‑gen MRI
Xenetix and Optiray are mature iodinated CT cash cows (iodinated >90% of CT contrast use in 2024), Dotarem is a stable MRI cash generator, Lipiodol is a niche high-margin product, and disposables/services provide recurring cash; Guerbet reported ~€1.15bn revenue in 2023 and directs cash to next-gen MRI and digital R&D.
| Product | Role | Metric |
|---|---|---|
| Xenetix/Optiray | CT cash cows | iodinated >90% (2024) |
| Dotarem | MRI cash flow | stable |
| Lipiodol | Niche cash | HCC incidence 905,677 (IARC 2020) |
| Consumables/Services | Recurring revenue | Guerbet €1.15bn (2023) |
Preview = Final Product
Guerbet BCG Matrix
The file you're previewing is the exact Guerbet BCG Matrix you'll receive after purchase—no watermarks, no placeholders. It's fully formatted and analysis-ready, built from market insights specific to Guerbet. No revisions needed. Buy and download instantly; it's editable, printable, and ready to present to stakeholders without surprises.
Actionable Strategy Starts Here
Curious where Guerbet’s products land—Stars, Cash Cows, Dogs or Question Marks? This snapshot teases the story; the full Guerbet BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a clear playbook for investment and divestment. Buy the complete report for a Word deep dive plus an Excel summary you can present and act on—fast, practical, and built for decision-makers.
Stars
Elucirem (gadopiclenol) MRI
Elucirem (gadopiclenol) sits squarely in the Star box: it addresses a high-growth MRI contrast segment (global MRI contrast market CAGR ~6% projected 2024–2030) with a best-in-class relaxivity profile that delivers pronounced image enhancement, driving strong clinical buzz and rapid uptake in premium imaging sites. It is grabbing share quickly where performance matters, but needs heavy medical education, robust post-marketing data and access work to sustain momentum; keep fueling it — this can mature into a major cash engine as the market steadies.
Dotarem franchise in fast-growth markets
In emerging regions Dotarem retains leader status as a macrocyclic gadoterate agent (FDA approval 2013) while MRI capacity expands rapidly—regional MRI device instalments growing an estimated 8–10% annually in 2024. Its strong safety profile and brand trust convert well as exam volumes rise, but defending tenders requires sustained commercial push and targeted pricing. Hold share now and as growth tapers the franchise transitions into a predictable cash cow.
Integrated injection platforms + software
Integrated injection platforms plus software form a hardware–software–consumables loop that locks in sites and follows the imaging market’s ~5.6% CAGR (2024–30), driving utilization and share as volumes rise. Capex-heavy to seed and train, the business yields sticky recurring consumables and service revenue; Guerbet, with ~1.06bn EUR 2023 sales, should keep investing in workflow, interoperability and the data layer to defend the beachhead.
Interventional imaging solutions (oncology focus)
Interventional imaging is structurally expanding alongside liver oncology and minimally invasive procedures; the interventional radiology market was ~USD 11.6B in 2023 and HCC accounted for 905,677 new cases in 2020, driving procedural volumes where Guerbet’s enhanced visualization and delivery solutions convert higher procedure counts into market share.
Clinical support and KOL training are primary growth levers; alignment with guideline-driven outcomes and real-world evidence cements leadership as adoption and repeat use rise.
- IR market ~USD 11.6B (2023)
- HCC incidence 905,677 new cases (2020)
- Levers: clinical support, KOL training, guideline/outcomes alignment
Strategic hospital partnerships
Long-term supply and service bundles in top health systems scale rapidly once embedded, with multi-year contracts (3–7 years) delivering roughly 30–50% greater revenue visibility and utilization predictability for vendors. As networks standardize protocols, preferred-vendor status locks market share and reduces churn. Set-up costs are real, so double down on multi-year value contracts and joint continuous-improvement plans to secure volume.
- Scale: rapid uptake in consolidated systems
- Lock-in: standardized protocols = preferred-vendor advantage
- Investment: absorb set-up costs for predictable volume
- Action: pursue 3–7 year contracts + joint improvement KPIs
Premium MRI contrast: high-growth market (~6% CAGR) — back access, KOLs, long contracts
Elucirem is a Star: premium MRI contrast in a ~6% CAGR global MRI market (2024–30) with rapid uptake; requires continued med-ed, RWE and access investment to scale. Dotarem holds regional leadership as capacity grows (~8–10% installs 2024 ME/EMEA). Invest in integrated platforms, KOLs and multi-year contracts to lock durable share.
| Asset | Role | Growth/Metric | 2023/24 |
|---|---|---|---|
| Elucirem | Star | MRI market CAGR | ~6% (2024–30) |
| Guerbet | Investor | Sales | €1.06bn (2023) |
| IR | Adj. growth | Market size | USD 11.6B (2023) |
What is included in the product
Detailed Word Document
BCG analysis of Guerbet's portfolio: spots Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Guerbet, highlights portfolio pain points and prioritizes fixes for faster decisions.
Cash Cows
Xenetix (iodinated CT)
Xenetix is a mature iodinated CT agent with a broad label and dependable volumes, reflecting that iodinated agents still represent over 90% of CT contrast use in 2024. Pricing is disciplined, tenders are established terrain and operations run efficiently, so promotional spend can stay modest while service reliability remains key. Strategy: milk margins, safeguard supply continuity, and steer clear of unnecessary price wars.
Optiray (ioversol) CT
Optiray (ioversol) is an established CT contrast brand in a slow-growth CT market, maintaining steady share through long-standing clinical familiarity and high formulary retention. Its cash generation remains strong relative to modest reinvestment needs, supporting margin stability and free cash flow. Prioritize quality maintenance, secure long-term supply and purchasing contracts, and channel surplus cash to fund higher-growth pipeline projects.
Dotarem in mature markets
Dotarem, a macrocyclic gadolinium-based MRI contrast agent established across US and EU markets, now sits past its steep growth phase and is recognized for stability and clinical trust.
It continues to generate steady cash flow despite newer MRI agents gaining attention, supported by minimal promotion and emphasis on access and reliable supply.
Guerbet directs those cash flows toward next-generation MRI agents and digital solutions, funding R&D and commercialization efforts.
Lipiodol niche indications
Lipiodol serves a smaller, highly specialized cash cow within Guerbet: resilient and profitable through niche indications such as transarterial chemoembolization for hepatocellular carcinoma and lymphography. Clinical utility keeps it relevant without heavy marketing spend; demand is predictable while supply assurance is the operational focus. Compliance and clean margins are critical to sustain cash generation.
- Used in TACE and lymphography
- Supports stable niche revenues
- Demand predictable; prioritize supply security
- Tight compliance to protect margins
- HCC incidence ~905,677 new cases (IARC 2020)
Disposables and service contracts
Disposables and service contracts deliver recurring, high-margin revenue for Guerbet; the group reported ~€1.15bn revenue in 2023, with consumables and services a core cash engine. Growth is low but churn remains minimal once platforms are installed, making forecasting straightforward. Promotion needs are light; focus is logistics and pricing to boost incremental cash.
- Recurring revenue
- High margin
- Low growth, low churn
- Easy forecasting
- Optimize logistics/pricing
CT iodinated >90% dominance funds €1.15bn R&D pivot to next‑gen MRI
Xenetix and Optiray are mature iodinated CT cash cows (iodinated >90% of CT contrast use in 2024), Dotarem is a stable MRI cash generator, Lipiodol is a niche high-margin product, and disposables/services provide recurring cash; Guerbet reported ~€1.15bn revenue in 2023 and directs cash to next-gen MRI and digital R&D.
| Product | Role | Metric |
|---|---|---|
| Xenetix/Optiray | CT cash cows | iodinated >90% (2024) |
| Dotarem | MRI cash flow | stable |
| Lipiodol | Niche cash | HCC incidence 905,677 (IARC 2020) |
| Consumables/Services | Recurring revenue | Guerbet €1.15bn (2023) |
Preview = Final Product
Guerbet BCG Matrix
The file you're previewing is the exact Guerbet BCG Matrix you'll receive after purchase—no watermarks, no placeholders. It's fully formatted and analysis-ready, built from market insights specific to Guerbet. No revisions needed. Buy and download instantly; it's editable, printable, and ready to present to stakeholders without surprises.
Description
Actionable Strategy Starts Here
Curious where Guerbet’s products land—Stars, Cash Cows, Dogs or Question Marks? This snapshot teases the story; the full Guerbet BCG Matrix gives quadrant-by-quadrant placement, data-backed recommendations, and a clear playbook for investment and divestment. Buy the complete report for a Word deep dive plus an Excel summary you can present and act on—fast, practical, and built for decision-makers.
Stars
Elucirem (gadopiclenol) MRI
Elucirem (gadopiclenol) sits squarely in the Star box: it addresses a high-growth MRI contrast segment (global MRI contrast market CAGR ~6% projected 2024–2030) with a best-in-class relaxivity profile that delivers pronounced image enhancement, driving strong clinical buzz and rapid uptake in premium imaging sites. It is grabbing share quickly where performance matters, but needs heavy medical education, robust post-marketing data and access work to sustain momentum; keep fueling it — this can mature into a major cash engine as the market steadies.
Dotarem franchise in fast-growth markets
In emerging regions Dotarem retains leader status as a macrocyclic gadoterate agent (FDA approval 2013) while MRI capacity expands rapidly—regional MRI device instalments growing an estimated 8–10% annually in 2024. Its strong safety profile and brand trust convert well as exam volumes rise, but defending tenders requires sustained commercial push and targeted pricing. Hold share now and as growth tapers the franchise transitions into a predictable cash cow.
Integrated injection platforms + software
Integrated injection platforms plus software form a hardware–software–consumables loop that locks in sites and follows the imaging market’s ~5.6% CAGR (2024–30), driving utilization and share as volumes rise. Capex-heavy to seed and train, the business yields sticky recurring consumables and service revenue; Guerbet, with ~1.06bn EUR 2023 sales, should keep investing in workflow, interoperability and the data layer to defend the beachhead.
Interventional imaging solutions (oncology focus)
Interventional imaging is structurally expanding alongside liver oncology and minimally invasive procedures; the interventional radiology market was ~USD 11.6B in 2023 and HCC accounted for 905,677 new cases in 2020, driving procedural volumes where Guerbet’s enhanced visualization and delivery solutions convert higher procedure counts into market share.
Clinical support and KOL training are primary growth levers; alignment with guideline-driven outcomes and real-world evidence cements leadership as adoption and repeat use rise.
- IR market ~USD 11.6B (2023)
- HCC incidence 905,677 new cases (2020)
- Levers: clinical support, KOL training, guideline/outcomes alignment
Strategic hospital partnerships
Long-term supply and service bundles in top health systems scale rapidly once embedded, with multi-year contracts (3–7 years) delivering roughly 30–50% greater revenue visibility and utilization predictability for vendors. As networks standardize protocols, preferred-vendor status locks market share and reduces churn. Set-up costs are real, so double down on multi-year value contracts and joint continuous-improvement plans to secure volume.
- Scale: rapid uptake in consolidated systems
- Lock-in: standardized protocols = preferred-vendor advantage
- Investment: absorb set-up costs for predictable volume
- Action: pursue 3–7 year contracts + joint improvement KPIs
Premium MRI contrast: high-growth market (~6% CAGR) — back access, KOLs, long contracts
Elucirem is a Star: premium MRI contrast in a ~6% CAGR global MRI market (2024–30) with rapid uptake; requires continued med-ed, RWE and access investment to scale. Dotarem holds regional leadership as capacity grows (~8–10% installs 2024 ME/EMEA). Invest in integrated platforms, KOLs and multi-year contracts to lock durable share.
| Asset | Role | Growth/Metric | 2023/24 |
|---|---|---|---|
| Elucirem | Star | MRI market CAGR | ~6% (2024–30) |
| Guerbet | Investor | Sales | €1.06bn (2023) |
| IR | Adj. growth | Market size | USD 11.6B (2023) |
What is included in the product
Detailed Word Document
BCG analysis of Guerbet's portfolio: spots Stars, Cash Cows, Question Marks and Dogs with clear invest, hold or divest guidance.
Customizable Excel Spreadsheet
One-page BCG matrix for Guerbet, highlights portfolio pain points and prioritizes fixes for faster decisions.
Cash Cows
Xenetix (iodinated CT)
Xenetix is a mature iodinated CT agent with a broad label and dependable volumes, reflecting that iodinated agents still represent over 90% of CT contrast use in 2024. Pricing is disciplined, tenders are established terrain and operations run efficiently, so promotional spend can stay modest while service reliability remains key. Strategy: milk margins, safeguard supply continuity, and steer clear of unnecessary price wars.
Optiray (ioversol) CT
Optiray (ioversol) is an established CT contrast brand in a slow-growth CT market, maintaining steady share through long-standing clinical familiarity and high formulary retention. Its cash generation remains strong relative to modest reinvestment needs, supporting margin stability and free cash flow. Prioritize quality maintenance, secure long-term supply and purchasing contracts, and channel surplus cash to fund higher-growth pipeline projects.
Dotarem in mature markets
Dotarem, a macrocyclic gadolinium-based MRI contrast agent established across US and EU markets, now sits past its steep growth phase and is recognized for stability and clinical trust.
It continues to generate steady cash flow despite newer MRI agents gaining attention, supported by minimal promotion and emphasis on access and reliable supply.
Guerbet directs those cash flows toward next-generation MRI agents and digital solutions, funding R&D and commercialization efforts.
Lipiodol niche indications
Lipiodol serves a smaller, highly specialized cash cow within Guerbet: resilient and profitable through niche indications such as transarterial chemoembolization for hepatocellular carcinoma and lymphography. Clinical utility keeps it relevant without heavy marketing spend; demand is predictable while supply assurance is the operational focus. Compliance and clean margins are critical to sustain cash generation.
- Used in TACE and lymphography
- Supports stable niche revenues
- Demand predictable; prioritize supply security
- Tight compliance to protect margins
- HCC incidence ~905,677 new cases (IARC 2020)
Disposables and service contracts
Disposables and service contracts deliver recurring, high-margin revenue for Guerbet; the group reported ~€1.15bn revenue in 2023, with consumables and services a core cash engine. Growth is low but churn remains minimal once platforms are installed, making forecasting straightforward. Promotion needs are light; focus is logistics and pricing to boost incremental cash.
- Recurring revenue
- High margin
- Low growth, low churn
- Easy forecasting
- Optimize logistics/pricing
CT iodinated >90% dominance funds €1.15bn R&D pivot to next‑gen MRI
Xenetix and Optiray are mature iodinated CT cash cows (iodinated >90% of CT contrast use in 2024), Dotarem is a stable MRI cash generator, Lipiodol is a niche high-margin product, and disposables/services provide recurring cash; Guerbet reported ~€1.15bn revenue in 2023 and directs cash to next-gen MRI and digital R&D.
| Product | Role | Metric |
|---|---|---|
| Xenetix/Optiray | CT cash cows | iodinated >90% (2024) |
| Dotarem | MRI cash flow | stable |
| Lipiodol | Niche cash | HCC incidence 905,677 (IARC 2020) |
| Consumables/Services | Recurring revenue | Guerbet €1.15bn (2023) |
Preview = Final Product
Guerbet BCG Matrix
The file you're previewing is the exact Guerbet BCG Matrix you'll receive after purchase—no watermarks, no placeholders. It's fully formatted and analysis-ready, built from market insights specific to Guerbet. No revisions needed. Buy and download instantly; it's editable, printable, and ready to present to stakeholders without surprises.
